Sales Performance - Total sales for the first quarter of 2025 reached $21,893 million, a 2.4% increase compared to $21,383 million in 2024[3] - U.S. sales increased by 5.9% to $12,305 million, while international sales decreased by 1.8% to $9,588 million[1] - Innovative Medicine segment reported a 2.3% increase in sales, while MedTech segment sales grew by 2.5%[2] - Oncology sales in the U.S. surged by 26.4% to $3,013 million, with international sales increasing by 9.6%[10] - The MedTech segment's total revenue for Q1 2025 was $2,103 million, reflecting a 16.4% increase compared to $1,806 million in Q1 2024[15] - Total MedTech segment sales reached $8,020 million in Q1 2025, a 2.5% increase compared to $7,821 million in Q1 2024[16] - U.S. MedTech sales grew by 5.1% to $4,213 million, while international sales slightly decreased by 0.2% to $3,807 million[16] - The Vision segment in the U.S. reported a 3.4% increase in sales, totaling $566 million, while international sales remained relatively flat with a 0.4% increase[16] Profitability - Gross profit decreased by 2.3% to $14,536 million, with a gross margin of 66.4% compared to 69.6% in the previous year[3] - Net earnings for the first quarter of 2025 were $10,999 million, a significant increase of 237.9% from $3,255 million in 2024[3] - Adjusted net earnings per share (diluted) rose to $2.77, a 2.2% increase from $2.71 in the previous year[5] Expenses and Taxation - The effective tax rate increased to 19.3% from 12.4% year-over-year[3] - Research and development expenses decreased by 8.9% to $3,225 million, representing 14.7% of sales[3] - The company initiated a restructuring program in the MedTech segment, incurring $55 million in expenses during the first quarter of 2025[6] Segment Performance - US sales in the Immunology segment decreased by 10.5% to $2,196 million, while international sales fell by 15.8% to $1,510 million[12] - The Neuroscience segment reported a 8.6% decline in worldwide sales, totaling $1,647 million, with US sales down 8.1% to $968 million[13] - Cardiovascular/Metabolism/Other segment in the US saw a significant increase of 35.4%, reaching $855 million, while international sales decreased by 19.7%[14] - XARELTO sales in the US increased by 33.3% to $690 million, contributing to a total of $690 million worldwide[14] - US sales for STELARA decreased by 29.8% to $981 million, with international sales down 38.9% to $644 million[12] - The Pulmonary Hypertension segment reported a worldwide revenue of $1,025 million, a decrease of 2.3% from $1,049 million in Q1 2024[13] - SPRAVATO sales in the US increased by 45.0% to $276 million, with worldwide sales reaching $320 million, up 41.9%[12] - The company reported a 2.9% decline in US sales for Infectious Diseases, totaling $315 million, while international sales decreased by 1.9% to $487 million[13] Future Projections - Innovative Medicine segment sales for the full year 2024 are projected to reach $2,225 million, with significant contributions from Pulmonary Hypertension products[18] - Rybrevant and Lazcluze generated $93 million in total sales in Q1 2024, with U.S. sales accounting for $36 million[18] - Talvey's sales in the U.S. for Q1 2024 were $50 million, with full-year expectations of $241 million[18] - Other Oncology products generated $328 million in total sales in Q1 2024, with U.S. sales at $93 million[18] - The company anticipates continued growth in the Pulmonary Hypertension segment, with Q1 2024 U.S. sales of $356 million[18] - International sales of Infectious Diseases products reached $1,395 million in Q1 2024, with U.S. sales at $19 million[18] - The overall operational growth for the MedTech segment was 4.1%, excluding currency effects[16]

强生公司将季度股息从每股1.24美元提高至1.30美元。 ...

Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period. Johnson & Johnson projects to report quarterly revenue at $21.57 billion, compared to $21.38 billion a year earlier, according to data from Benzinga Pro. Protagonist Therapeutics, on April 10, announced new data for a pill that trea ...

Core Viewpoint - The analysis emphasizes the potential of Johnson & Johnson (JNJ) stock as a "Buy" due to its competitive advantages and defensibility in the market [1]. Group 1: Company Analysis - Johnson & Johnson is identified as a high-quality company capable of outperforming the market over the long term [1]. - The analysis focuses on companies with a competitive advantage, referred to as an economic moat, which enhances their market position [1]. - The investment strategy is not limited by market capitalization, allowing for a broader range of investment opportunities from large cap to small cap companies [1]. Group 2: Analyst Background - The analyst has a Master's Degree in Sociology with a focus on organizational and economic sociology, and a Bachelor's Degree in Sociology and History [1].

Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its first-quarter 2025 results on April 15. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $21.66 billion and $2.57 per share, respectively. The Zacks Consensus Estimate for J&J’s earnings has declined from $10.58 per share to $10.57 per share for 2025, while that for 2026 has declined from $11.07 per share to $11.02 per share over the past 60 days.Find the latest EPS estimate ...

Wall Street analysts expect Johnson & Johnson (JNJ) to post quarterly earnings of $2.57 per share in its upcoming report, which indicates a year-over-year decline of 5.2%. Revenues are expected to be $21.66 billion, up 1.3% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.3% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals i ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16SPRING HOUSE, Pa., April 10, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from a subgroup analysis of ICONIC-LE ...

Stock market sell-offs like the one we're currently experiencing are challenging periods for investors. However, with every challenge comes an opportunity to improve. For me, sell-offs are an opportunity to buy high-quality dividend stocks at lower prices, which enables me to lock in higher dividend yields. That allows me to generate even more passive income, which I can reinvest in producing additional income until I reach the point where it can cover my living expenses and I can retire. I'm currently capi ...

While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.The Johnson & Johnson Analyst: Analyst Asad Haider upgraded the rating from Neutral to Buy, while raising the price target from $157 to $172.The Johnson & Johnson Thesis: While the Innovative Medicine business contributes around 65% of the company's revenues, it accounts for 83% of profits, which is why it is " ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]